MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY lobbying for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$610,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Lobbyists on this filing 2

BRIAN BRANTON

Previously held: Chief of Staff, Congressman Polis; Chief of Staff, Congressman Sestak; Legislative Director, Congressman Wu; Legislative Counsel, Congressman Holt; Legislative Assistant, Congresswoman Mink
SHANA BEAVIN New on this filing

Previously held: Prof. Staff Member, House Energy & Commerce Committee Minority Staff; Program Analyst, Centers for Disease Control and Prevention; Leg. Dir., Rep. Jim Matheson.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

H.R. 3521, Clinical Trial Modernization Act; H.R. 1, One Big Beautiful Bill (Definition clarity around distributors); S. 3822, Break Up Big Medicine Act; Issues related to support for independent physician practices, community pharmacies, and community-based care; Drug Shortages; Safe Step Act (not reintroduced in 119th) (Support establishing an exception to medication step-therapy protocol in specified cases).

Medicare/Medicaid

H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.

Pharmacy

H.R. 3164, Ensuring Community Access to Pharmacist Services Act.

Manufacturing

H.R. 2444, Promoting Resilient Supply Chains Act; S.257, Promoting Resilient Supply Chains.

Bills named in this filing 12

H.R. 3521
Clinical Trial Modernization Act
H.R. 1
One Big Beautiful Bill Act
S. 3822
Break Up Big Medicine Act
H.R. 2484
Seniors’ Access to Critical Medications Act of 2025
H.R. 879
Medicare Patient Access and Practice Stabilization Act of 2025
H.R. 2120
ROCR Value Based Program Act
S. 1816
Improving Seniors’ Timely Access to Care Act of 2025
H.R. 3514
Improving Seniors’ Timely Access to Care Act of 2025
H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 3164
Ensuring Community Access to Pharmacist Services Act
H.R. 2444
Promoting Resilient Supply Chains Act of 2025
S. 257
Promoting Resilient Supply Chains Act of 2025